Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Fast track designation for MDX-010 in metastatic melanoma

Oct. 7, 2004

Stellar Biotechnologies awarded NCI grant for KLH development

Oct. 7, 2004

Triton BioSystems licenses ING-1 antibody from Xoma

Oct. 7, 2004

TACI-Ig cleared to enter phase Ib studies in advanced B-cell malignancies

Oct. 6, 2004

Kissei takes option to Japanese license for YSCMA

Oct. 5, 2004

Enrollment opens in phase III trial of MDX-010 for metastatic melanoma

Oct. 4, 2004

Epimmune plans phase II study of EP-2101 cancer vaccine

Oct. 1, 2004

L-BLP-25 liposome vaccine receives fast track status for NSCLC

Oct. 1, 2004

IL-2 does not influence pharmacokinetics of CNTO-328 in monkeys

Sep. 30, 2004

Third indication studied for SGN-30 in new phase II trial

Sep. 29, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...